Logo image of TPST

TEMPEST THERAPEUTICS INC (TPST) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TPST - US87978U2078 - Common Stock

2.91 USD
-0.03 (-1.02%)
Last: 12/16/2025, 8:00:01 PM
2.91 USD
0 (0%)
After Hours: 12/16/2025, 8:00:01 PM
Fundamental Rating

2

Overall TPST gets a fundamental rating of 2 out of 10. We evaluated TPST against 529 industry peers in the Biotechnology industry. The financial health of TPST is average, but there are quite some concerns on its profitability. TPST does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TPST has reported negative net income.
In the past year TPST has reported a negative cash flow from operations.
TPST had negative earnings in each of the past 5 years.
In the past 5 years TPST always reported negative operating cash flow.
TPST Yearly Net Income VS EBIT VS OCF VS FCFTPST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

TPST has a worse Return On Assets (-210.49%) than 90.17% of its industry peers.
TPST has a worse Return On Equity (-568.14%) than 77.32% of its industry peers.
Industry RankSector Rank
ROA -210.49%
ROE -568.14%
ROIC N/A
ROA(3y)-78.49%
ROA(5y)-71.6%
ROE(3y)-175.41%
ROE(5y)-142.93%
ROIC(3y)N/A
ROIC(5y)N/A
TPST Yearly ROA, ROE, ROICTPST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

TPST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TPST Yearly Profit, Operating, Gross MarginsTPST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, TPST has more shares outstanding
Compared to 5 years ago, TPST has more shares outstanding
Compared to 1 year ago, TPST has an improved debt to assets ratio.
TPST Yearly Shares OutstandingTPST Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
TPST Yearly Total Debt VS Total AssetsTPST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TPST has an Altman-Z score of -24.63. This is a bad value and indicates that TPST is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TPST (-24.63) is worse than 86.39% of its industry peers.
TPST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.63
ROIC/WACCN/A
WACCN/A
TPST Yearly LT Debt VS Equity VS FCFTPST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TPST has a Current Ratio of 2.30. This indicates that TPST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.30, TPST is doing worse than 73.53% of the companies in the same industry.
A Quick Ratio of 2.30 indicates that TPST has no problem at all paying its short term obligations.
The Quick ratio of TPST (2.30) is worse than 71.46% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
TPST Yearly Current Assets VS Current LiabilitesTPST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.76% over the past year.
EPS 1Y (TTM)50.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TPST will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.92% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.15%
EPS Next 2Y7.8%
EPS Next 3Y9.22%
EPS Next 5Y11.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TPST Yearly Revenue VS EstimatesTPST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2028 2030 2031 2032 50M 100M 150M 200M
TPST Yearly EPS VS EstimatesTPST Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2K -4K -6K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TPST. In the last year negative earnings were reported.
Also next year TPST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TPST Price Earnings VS Forward Price EarningsTPST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TPST Per share dataTPST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.8%
EPS Next 3Y9.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TPST!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (12/16/2025, 8:00:01 PM)

After market: 2.91 0 (0%)

2.91

-0.03 (-1.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners11.89%
Inst Owner Change-64.34%
Ins Owners0.11%
Ins Owner Change0%
Market Cap14.35M
Revenue(TTM)N/A
Net Income(TTM)-36.05M
Analysts43.33
Price Target9.18 (215.46%)
Short Float %7.71%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.21%
Min EPS beat(2)22.1%
Max EPS beat(2)76.31%
EPS beat(4)3
Avg EPS beat(4)20.93%
Min EPS beat(4)-20.6%
Max EPS beat(4)76.31%
EPS beat(8)5
Avg EPS beat(8)9.95%
EPS beat(12)8
Avg EPS beat(12)10.82%
EPS beat(16)11
Avg EPS beat(16)10.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.26
P/tB 2.26
EV/EBITDA N/A
EPS(TTM)-10.05
EYN/A
EPS(NY)-16.34
Fwd EYN/A
FCF(TTM)-6.77
FCFYN/A
OCF(TTM)-6.77
OCFYN/A
SpS0
BVpS1.29
TBVpS1.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -210.49%
ROE -568.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-78.49%
ROA(5y)-71.6%
ROE(3y)-175.41%
ROE(5y)-142.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.2%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -24.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.31%
Cap/Depr(5y)60.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.18%
EPS Next Y33.15%
EPS Next 2Y7.8%
EPS Next 3Y9.22%
EPS Next 5Y11.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.55%
EBIT Next 3Y-27.03%
EBIT Next 5Y-26.77%
FCF growth 1Y-18.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.73%
OCF growth 3YN/A
OCF growth 5YN/A

TEMPEST THERAPEUTICS INC / TPST FAQ

What is the ChartMill fundamental rating of TEMPEST THERAPEUTICS INC (TPST) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TPST.


Can you provide the valuation status for TEMPEST THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to TEMPEST THERAPEUTICS INC (TPST). This can be considered as Overvalued.


Can you provide the profitability details for TEMPEST THERAPEUTICS INC?

TEMPEST THERAPEUTICS INC (TPST) has a profitability rating of 0 / 10.


Can you provide the financial health for TPST stock?

The financial health rating of TEMPEST THERAPEUTICS INC (TPST) is 5 / 10.